Skip to main content

Table 1 Demographic and clinical characteristics of hospitalised patients with an associated diagnosis of erythema multiforme (EM) or Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN); Mainland Portugal, 2009–2014 (n = 254 hospitalisations)

From: Stevens–Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database

Characteristics

Cutaneous adverse reactions

SJS/TEN

EMa (N = 122)

SJS/TEN (N = 132)

P value

Stevens–Johnson Syndrome (N = 73)

SJS–TEN overlapb (N = 18)

Toxic epidermal necrolysis (N = 41)

P value

Episodes as main diagnosis—n (%)

34 (27.9)

89 (66.4)

 

45 (61.6)

14 (77.8)

30 (68.3)

 

6-years incidence (per million inhabitants)

12.2

13.2

 

7.3

1.8

4.1

 

Gender—n (%)

 Male

43 (35.2)

60 (45.5)

0.098

34 (46.6)

9 (50.0)

17 (41.5)

0.798

 Female

79 (64.8)

72 (54.5)

 

39 (53.4)

9 (50.0)

25 (58.5)

 

Age (years)

 Median (percentile 25–75)

63 (44–77)

63 (45–75)

0.903

64 (46–79)

57 (34–72)

65 (48–74)

0.492

Comorbidities

 Hypertension

39 (32.0)

46 (34.8)

0.627

29 (39.7)

5 (27.8)

12 (29.3)

0.422

 Diabetes

19 (15.6)

22 (16.7)

0.813

13 (17.8)

4 (22.2)

5 (12.2)

0.589

 Heart failure

10 (8.2)

13 (9.8)

0.647

8 (11.0)

3 (16.7)

2 (4.9)

0.272

 Chronic kidney disease

12 (9.8)

15 (11.4)

0.693

7 (9.6)

4 (22.2)

4 (9.8)

0.340

 Liver disease

11 (9.0)

10 (7.6)

0.677

4 (5.5)

3 (16.7)

3 (7.3)

0.203

  Acute toxic hepatitis

7 (5.7)

6 (4.5)

0.882

2 (2.7)

2 (11.1)

2 (4.9)

0.269

 HIV

2 (1.6)

12 (9.1)

0.009

8 (11.0)

3 (16.7)

1 (2.4)

0.115

Length-of-stayc (days)

 Median (percentile 25–75)

10 (5–20)

15 (7–28)

0.007

15 (7–23)

23 (9–36)

14 (7–28)

0.456

In-hospital mortality—n (%)

9 (7.4)

32 (24.2)

< 0.001

12 (16.4)

2 (11.1)

18 (43.9)

0.002

  1. aEncompasses 5 cases of EM minor, 11 cases of EM major, 10 cases of other forms of EM, and 96 cases of unspecified EM
  2. bStevens–Johnson and toxic epidermal necrolysis overlap syndrome
  3. cIncludes all episodes, including those resulting in the death of patients